- Home
- OVID vs AQST Comparison
OVID vs AQST Comparison
Compare OVID & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OVID | AQST |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.9M | 529.4M |
| IPO Year | 2017 | 2007 |
Fundamental Metrics
Financial Performance| Metric | OVID | AQST |
|---|---|---|
| Price | $2.56 | $3.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | $6.40 | ★ $9.33 |
| AVG Volume (30 Days) | 2.4M | ★ 2.6M |
| Earning Date | 11-10-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.90 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,252,000.00 | ★ $67,430,000.00 |
| Revenue This Year | N/A | $11.13 |
| Revenue Next Year | N/A | $40.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1181.27 | 0.77 |
| 52 Week Low | $1.18 | $2.94 |
| 52 Week High | $3.11 | $6.74 |
Technical Indicators
Market Signals| Indicator | OVID | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 50.37 | 34.71 |
| Support Level | $2.12 | N/A |
| Resistance Level | $2.67 | $4.34 |
| Average True Range (ATR) | 0.24 | 0.23 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 44.95 | 23.37 |
Price Performance
Historical ComparisonAbout OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.